Comparative efficacy of incretin drugs on glycemic control, body weight, and blood pressure in adults with overweight or obesity and with/without type 2 diabetes: a systematic review and network meta-analysis

医学 2型糖尿病 内科学 糖化血红素 超重 血糖性 荟萃分析 人口 安慰剂 糖尿病 随机对照试验 肥胖 内分泌学 胰岛素 病理 替代医学 环境卫生
作者
Song Liu,Jiaqiang Hu,Chen Zhao,Hang Liu,He Chunyang
出处
期刊:Frontiers in Endocrinology [Frontiers Media]
卷期号:16: 1513641-1513641 被引量:19
标识
DOI:10.3389/fendo.2025.1513641
摘要

Background The rapid development of multi-receptor drugs targeting glucagon-like peptide-1 receptor (GLP-1R) is driving significant advancements in the treatment of individuals with type 2 diabetes and obesity. This systematic review and network meta-analysis aims to compare the efficacy and safety of multi-receptor drugs in adults with overweight or obesity, with or without type 2 diabetes. Methods A systematic search was conducted in PubMed, Cochrane, Web of Science, Embase, CNKI, and WanFang databases up to May 12, 2024. Randomized controlled trials (RCTs) with an intervention duration of at least 12 weeks were included. The population of interest consisted of individuals with overweight or obesity, with or without type 2 diabetes. Eligible studies compared multi-receptor drugs with placebo or other multi-receptor drugs. The primary outcomes were weight reduction, glycated hemoglobin (HbA 1c ), fasting plasma glucose (FPG), blood pressure changes, and adverse events. Risk of bias was assessed using the version 2 of the Cochrane risk-of-bias tool (ROB2), and a random-effects network meta-analysis was performed using the frequentist approach. Confidence in effect estimates was evaluated using the Confidence In Network Meta-Analysis (CINeMA) framework. Results A total of 24 trials, involving 9165 participants, were included. Retatrutide (mean difference (MD): -11.91 kg, 95% CI: -19.00 to -4.82, P-score: 0.80, p: 0.0003) and Tirzepatide (MD: -12.78 kg, 95% CI: -16.10 to -9.46, P-score: 0.89, p < 0.0001) exhibited superior efficacy in reducing body weight, with all other agents except Mazdutide (MD: -5.31 kg, 95% CI: -9.78 to -0.84, P-score: 0.37, p: 0.0189) achieving reductions of over 8 kg. In patients with type 2 diabetes, all agents reduced HbA 1c by over 1%, with Tirzepatide (MD: -1.87%, 95% CI: -2.15 to -1.59, P-score: 0.87, p < 0.0001) and Mazdutide (MD: -1.89%, 95% CI: -2.43 to -1.35, P-score: 0.88, p < 0.0001) showing the greatest effects on glycemic control. For blood pressure management, Tirzepatide significantly reduced systolic blood pressure (MD: -6.69 mmHg, 95% CI: -7.62 to -5.75, P-score: 0.84, p < 0.0001) and diastolic blood pressure (MD: -3.73 mmHg, 95% CI: -4.75 to -2.71, P-score: 0.92, p < 0.0001), with nearly all agents lowering systolic blood pressure by more than 5 mmHg. Non-diabetic participants showed more pronounced improvements in both weight and blood pressure. Safety analysis revealed that Tirzepatide had a favorable safety profile and all agents showed no significant impact on serious adverse events compared to placebo. Conclusions Multi-receptor drugs demonstrated substantial therapeutic potential in weight management, glycemic control, and blood pressure regulation in adults with overweight or obesity, with or without diabetes, with a generally favorable safety profile. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD42024554005.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
guopan完成签到,获得积分10
1秒前
无奈夏菡完成签到 ,获得积分10
1秒前
雷霆大香蕉完成签到,获得积分10
1秒前
zzgpku完成签到,获得积分0
2秒前
Yanping完成签到,获得积分10
3秒前
丨墨月丨完成签到,获得积分0
3秒前
just完成签到 ,获得积分10
4秒前
5秒前
5秒前
风趣小蜜蜂完成签到 ,获得积分10
6秒前
荔枝完成签到,获得积分10
6秒前
卷心菜本菜完成签到,获得积分10
7秒前
生椰拿铁完成签到 ,获得积分10
8秒前
小高完成签到,获得积分10
8秒前
ljhwahaha完成签到,获得积分10
9秒前
故意的亦竹完成签到,获得积分10
10秒前
Auster发布了新的文献求助10
10秒前
Yanghh完成签到,获得积分10
10秒前
风中的棒棒糖完成签到 ,获得积分10
10秒前
Zhuideal完成签到,获得积分10
11秒前
Lion完成签到,获得积分10
11秒前
虚晃完成签到,获得积分10
12秒前
const完成签到,获得积分10
12秒前
zhen发布了新的文献求助10
12秒前
爆米花的应助被KYTYYDS采纳,获得10
12秒前
Rosaline完成签到,获得积分10
12秒前
残月下的樱花完成签到,获得积分10
13秒前
Casey完成签到,获得积分10
13秒前
吴秋阳完成签到 ,获得积分10
13秒前
纸条条完成签到 ,获得积分10
14秒前
风信子完成签到,获得积分0
15秒前
TheDing完成签到,获得积分10
15秒前
夏天完成签到,获得积分10
15秒前
vanliu完成签到,获得积分10
18秒前
小知了完成签到,获得积分10
18秒前
wanci的应助被风中的眼神采纳,获得10
18秒前
公西元风完成签到,获得积分10
18秒前
错过的风景完成签到,获得积分10
19秒前
潇洒的小懒猪完成签到,获得积分10
19秒前
Daria完成签到 ,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166570
求助须知:如何正确求助?哪些是违规求助? 9559581
关于积分的说明 21750904
捐赠科研通 7757397
什么是DOI,文献DOI怎么找? 3429170
关于科研通互助平台的介绍 2553530
邀请新用户注册赠送积分活动 2473923